Antibiotic resistance is a growing public health problem that has been made more significant by the fact that major pharmaceutical companies have largely divested from the discovery of new antibacterial agents. My laboratory is interested in the discovery of new antibacterial agents that work on novel targets. In this seminar, we will talk about two projects. The first is the discovery of spore germination inhibitors for the prevention of C. difficile infections. C. difficile is a growing problem that has been recognized by the CDC as a public health crisis due to the increasing numbers of infections as well as the rise of hypervirulent strains. We, along with our collaborators, have found agents that work to prevent the germination of C. difficile spores, and thus prevent the infection. The second project focuses on targeting de novo purine biosynthesis. Previous studies have shown that purine biosynthesis is different between microbes and humans. We have conducted numerous experiments aimed at finding inhibitors of key microbial enzymes involved in the pathway. In this seminar, I will talk about our high-throughput screening results (and their challenges) as well as approaches towards using kinase inhibitors as lead agents for drug development of antibacterial agents.
Antiinfective Drug Discovery; Organic Chemistry; Biochemistry; Chemical Biology
Dr. Firestine's profile from Wayne State.